The recent sell-off in Hims & Hers Health (HIMS) is viewed as a buying opportunity, as legal and competitive threats are considered overstated. For long-term exposure to the weight-loss market, Eli Lilly (LLY) is positioned to dominate with its next-generation drug retatrutide, expected around late 2026. Investors should be cautious on Novo Nordisk (NVO) due to significant long-term risks from both compounded alternatives and superior competition from LLY. The entire GLP-1 drug theme is a short-term opportunity that will likely be disrupted within the next 2-3 years. Lastly, coupon providers like GoodRx (GDRX) are considered unattractive investments with weak business models and should be avoided.

Hims & Hers Health, Inc. (HIMS)

• The speaker believes the stock is currently under a "FUD attack" (Fear, Uncertainty, and Doubt), causing a recent price drop, which they view as an overreaction.
• The primary concerns driving the stock down are threats of legal action from Novo Nordisk (NVO) and the FDA over HIMS's new compounded oral semaglutide product, as well as perceived competition from TrumpRx.
• Bullish Case on Legal Threats: The speaker argues HIMS is in a win-win situation regarding a potential lawsuit from NVO.
  • If no lawsuit: HIMS gets to sell its oral compounded semaglutide, priced very competitively at $49.
  • If there is a lawsuit:
    • Court cases take a long time (estimated 3-6 years), by which point the GLP-1 market will be completely different.
    • HIMS is not copying NVO's patented SNAC oral delivery system; it uses a different, non-patented liposomal delivery system.
    • A lawsuit could bring a major legal question to the forefront: can naturally occurring peptides be patented? A ruling in HIMS's favor could open the door for compounding many other drugs.
    • Public opinion is strongly against high drug prices, which could influence a judge's decision in HIMS's favor.
    • The speaker notes that Big Pharma has much more to lose from a legal precedent that favors compounding than HIMS does.
• Business Model Strength:
  • The core of HIMS's value proposition is personalization at scale using AI. They create compounded, personalized medications ("one person, one drug") to optimize dosage and minimize side effects.
  • GLP-1 weight loss drugs represent less than 25% of HIMS's total business. The market is incorrectly viewing HIMS as only a GLP-1 company.
  • HIMS is expanding into other areas like at-home labs, cancer testing, and other types of peptides.
• Competition from TrumpRx: The speaker dismisses TrumpRx as a "non-event" and not a real threat.
  • It's described as a simple coupon provider, similar to GoodRx, not an integrated telehealth platform like HIMS.
  • It does not solve the problem of expensive and inconvenient doctor's visits needed to get a prescription.

Takeaways

• The speaker is very bullish on HIMS. They believe the market is misunderstanding the legal risks and the company's diversified business model.
• The recent stock decline could be a buying opportunity for investors who believe in the speaker's analysis that the legal and competitive threats are overblown.
• The long-term investment thesis for HIMS is its technology-driven, personalized medicine platform, not just its participation in the short-term GLP-1 trend.

Novo Nordisk (NVO)

• NVO is the maker of semaglutide (Ozempic, Wegovy) and is seen as the primary antagonist threatening HIMS with legal action over its compounded version.
• Potential Weaknesses Mentioned:
  • The speaker questions NVO's connection to the US market, citing a press release written in "British English" as a sign of a potential disconnect.
  • NVO faces a significant "innovator's dilemma." A court ruling that upholds mass compounding would create a massive loophole, severely threatening their high-priced drug model, particularly in the US, their most profitable market.
  • The speaker believes NVO's current blockbuster drug, semaglutide, will be made largely obsolete by Eli Lilly's next-generation drug, retatrutide, by late 2026.

Takeaways

• The speaker presents a bearish/cautious outlook on NVO due to the dual threats of compounded alternatives and superior next-generation drugs from competitors.
• Investors in NVO should be aware of the risk that a legal battle with HIMS could backfire and set a dangerous precedent for the entire pharmaceutical industry's pricing power.
• The long-term dominance of NVO in the weight-loss market is at risk from competition.

Eli Lilly and Company (LLY)

• LLY is the creator of tirzepatide (Mounjaro, Zepbound) and is developing a next-generation GLP-1 drug called retatrutide.
• The speaker is extremely bullish on LLY's future position in the weight-loss market.
• They predict that once retatrutide is approved (expected in late 2026), LLY will "own the entire market."
• Retatrutide is expected to be so effective that it will not only "kill" demand for NVO's semaglutide but also cannibalize LLY's own successful tirzepatide product.

Takeaways

• The speaker has a strong bullish long-term view on LLY.
• LLY is positioned to become the undisputed leader in the lucrative weight-loss drug market by 2026-2027 with its pipeline of next-generation drugs.
• This suggests LLY may be a better long-term investment for exposure to the GLP-1 theme than NVO.

Investment Theme: GLP-1 Drugs

• The speaker views the current GLP-1 market as a "very short-term conversation."
• The opportunity is about "how many hundreds of millions you want to make in the next five to six months" before the market landscape changes dramatically.
• The entire market is expected to be disrupted by the FDA approval of Eli Lilly's retatrutide in late 2026.

Takeaways

• Investing in the GLP-1 space is a fast-moving and high-risk, high-reward endeavor.
• The current market leaders and dynamics are likely temporary. Investors should be prepared for significant disruption within the next 2-3 years.
• The key event to watch is the development and approval timeline for Eli Lilly's retatrutide.

GoodRx (GDRX)

• Mentioned in comparison to the new TrumpRx service.
• The speaker describes GDRX as an "uninteresting business" with "very small margins."

Takeaways

• The speaker has a bearish sentiment on GDRX.
• The business model of providing drug coupons is viewed as having low profitability and is not considered an attractive investment.